[
  {
    "ts": null,
    "headline": "Why Analysts See DexCom’s Outlook Shifting Amid New Leadership and Changing Growth Drivers",
    "summary": "DexCom’s Fair Value Estimate has recently been revised downward, moving modestly from $102.08 to $100.54 per share. This change reflects subtle shifts in analyst sentiment. While the company still enjoys strong growth prospects, changes in industry outlook and evolving business dynamics have tempered enthusiasm for more aggressive price targets. Stay tuned to discover how investors can stay ahead of the narrative as new updates continue to shape DexCom’s trajectory. What Wall Street Has Been...",
    "url": "https://finnhub.io/api/news?id=4b65b09f58831c52f509720484a8418c102212559ecaa3a13f692ec395ccd3af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759585021,
      "headline": "Why Analysts See DexCom’s Outlook Shifting Amid New Leadership and Changing Growth Drivers",
      "id": 136981421,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom’s Fair Value Estimate has recently been revised downward, moving modestly from $102.08 to $100.54 per share. This change reflects subtle shifts in analyst sentiment. While the company still enjoys strong growth prospects, changes in industry outlook and evolving business dynamics have tempered enthusiasm for more aggressive price targets. Stay tuned to discover how investors can stay ahead of the narrative as new updates continue to shape DexCom’s trajectory. What Wall Street Has Been...",
      "url": "https://finnhub.io/api/news?id=4b65b09f58831c52f509720484a8418c102212559ecaa3a13f692ec395ccd3af"
    }
  }
]